Pyridoxylamine |
| Catalog No.GC31581 |
La piridoxilamina es un inhibidor avanzado de la producciÓn final de la glicaciÓn (AGE) y de los productos finales de la lipoxidaciÓn (ALE), para proteger contra las lesiones vasculares de la retina inducidas por la diabetes.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 85-87-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Pyridoxylamine is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions.
Pyridoxylamine (PM), a member of the B6 vitamer family, is a potent scavenger of reactive carbonyls, inhibiting the late stages of glycation reactions that lead to AGE formation[1].
Pyridoxylamine limits the formation of CML and CEL and cross-linking in skin collagen and, ultimately inhibits the development of nephropathy in STZ-diabetic rats. Pyridoxylamine does not appear to function as an antioxidant since it does not prevent lipid peroxidation reactions. At the same time, it does prevent protein modification by products of lipid peroxidation, including inhibiting formation of malondialdehyde and 4-hydroxynonenal adducts on protein in Zucker rats in vivo[1].
[1]. Stitt A, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes. 2002 Sep;51(9):2826-32.
Average Rating: 5 (Based on Reviews and 19 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *